| [1] |
Younas A, Sundus A, Inayat S. Transitional experience of men with breast cancer from diagnosis to survivorship: An integrative review[J]. Eur J Oncol Nurs，2019, 10(42)：141-152.
|
| [2] |
Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10159 cases from 12 studies[J]. PLoS Med，2010，7(5): e1 000 279.
|
| [3] |
Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline[J]. J Clin Oncol，2016，34(25)：3069-3103.
|
| [4] |
Reinert T, Debiasi M, Bines J, et al. Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer[J]. Breast Cancer Res Treat，2018，168 (2)：457-465.
|
| [5] |
Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors[J]. Clin Cancer Res，2017，23(13)：3251-3262.
|
| [6] |
Sutherland RL, Musgrove EA. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease[J]. Breast Cancer Res，2009，11(6)：112.
|
| [7] |
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER-2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study[J]. Lancet Oncol，2015，16(1)：25-35.
|
| [8] |
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med，2016，375(20)：1925-1936.
|
| [9] |
Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER-2- negative advanced breast cancer[J]. Ann Oncol，2018, 29(7)：1541-1547.
|
| [10] |
Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol，2018，19(7)：904-915.
|
| [11] |
Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol，2017，35(32)：3638-3646.
|
| [12] |
Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA Approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER-2-negative metastatic breast cancer[J]. Clin Cancer Res，2015，21(21)：4760-4766.
|
| [13] |
DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment[J]. Clin Cancer Res，2015，21(5)：995-1001.
|
| [14] |
Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer[J]. Cancer Treat Rev，2016，45：129-38.
|
| [15] |
Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer[J]. Breast Care (Basel)，2016，11(3)：167-173.
|
| [16] |
Rugo HS, Turner NC, Finn RS, et al. Palbociclib plus endocrine therapy in older women with HR+/HER-2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies[J]. Eur J Cancer，2018，101：123-133.
|
| [17] |
Sonke GS, Hart LL, Campone M, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER-2-negative breast cancer in the randomized MONALEESA-2 trial[J]. Breast Cancer Res Treat，2018，167(3)：659-669.
|
| [18] |
Singh H, Howie L, Bloomquist E, et al. A U．S. Food and Drug Administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy[C/OL]// San Antonio Breast Cancer Symposium, San Antonio, 2018[2020-01-25]．
URL
|
| [19] |
Schröder J, Fietz T, Kohler A, et al. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer-results from the prospective German Tumour Registry Breast Cancer cohort study[J]. Eur J Cancer，2017，79：139-148.
|
| [20] |
Goetz MP, O’Shaughnessy J, Sledge GW, et al. The benefit of abemaciclib in prognostic subgroups: an exploratory analysis of combined data from the MONARCH 2 and 3 studies[EB/OL]. [2020-01-25]．
URL
|
| [21] |
Turner NC, Finn RS, Martin M, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases[J]. Ann Oncol，2018，29(3)：669-680.
|
| [22] |
Burris HA, Chan A, Campone M, et al. First-line ribociclib + letrozole in patients with HR+，HER-2- advanced breast cancer presenting with visceral metastases or bone-only disease: a subgroup analysis of the MONALEESA-2 trial[EB/OL]. [2020-01-25]．
URL
|
| [23] |
Janni W, Alba E, Bachelot T, et al. First-line ribociclib plus letrozole in postmenopausal women with HR+，HER-2- advanced breast cancer: tumor response and pain reduction in the phase 3 MONALEESA-2 trial[J]. Breast Cancer Res Treat，2018，169(3)：469-479.
|
| [24] |
Sammons SL, Topping DL, Blackwell KL. HR+，HER-2- advanced breast cancer and CDK4/6 inhibitors: mode of action, clinical activity, and safety profiles[J]. Curr Cancer Drug Targets，2017，17(7)：637-649.
|
| [25] |
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol，2015，33(28)：3199-3212.
|
| [26] |
Dieras V, Harbeck N, Joy AA, et al. PALOMA-2: Neutropenia patterns in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative first-line advanced breast cancer receiving palbociclib plus letrozole[EB/OL]. [2020-01-25]．
URL
|
| [27] |
Janni W, Burris HA, Blackwell KL, et al. First-line ribociclib+letrozole for postmenopausal women with HR+，HER-2- ABC: MONALEESA-2 safety results[EB/OL]. [2020-01-25]．
URL
|
| [28] |
Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER-2- negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18[J]. Breast Cancer Res，2016，18(1)：67.
|
| [29] |
Eli Lilly.Verzenio[EB/OL]．[2020-01-25].
URL
|
| [30] |
Novartis Pharmaceuticals Corporation.Highlight of prescribing information[EB/OL]．[2020-01-25]．
URL
|
| [31] |
Vandenberk B, Vandael E, Robyns T, et al. Which QT correction formulae to use for QT monitoring? [J]. J Am Heart Assoc，2016，5(6): e003264.
|
| [32] |
Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation[J]. J Am Coll Cardiol，2010，55(9)：934-947.
|
| [33] |
Bell T, Crown JP, Lang I, et al. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment[J]. Curr Med Res Opin，2016，32(5)：959-965.
|
| [34] |
Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, et al. CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy[EB/OL]. [2020-01-25].
URL
|
| [35] |
Finn RS, Liu Y, Martin M, et al. Comprehensive gene expression biomarker analysis of cyclin-dependent kinases 4/6 and endocrine pathways from the PALOMA-2 study[EB/OL]. [2020-01-25].
URL
|
| [36] |
Andre F, Stemmer SM, Campone M, et al. Ribociclib + letrozole for first-line treatment of HR+，HER-2- advanced breast cancer: efficacy by baseline tumor markers[EB/OL]. [2020-01-25]．
URL
|
| [37] |
Malorni L, Curigliano G, Minisini AM, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER-2-negative metastatic breast cancer: TREnd trial[J]. Ann Oncol，2018，29(8)：1748-1754.
|
| [38] |
Moulder S, Karuturi M, Yardley DA, et al. Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER-2 advanced breast cancer after progression on a CDK4/6 inhibitor: efficacy and safety results from phase 2 of the TRINITI-1 study[EB/OL]. [2020-01-25].
URL
|